Abstract:Highlights • Explored sirolimus-encapsulated biodegradable polymeric coatings for drug-eluting stents in the treatment of arterial diseases, addressing safety concerns related to non-biodegradable polymers and cytotoxic drugs. • Delivery of safer therapeutic: anti-proliferative cytostatic agent. • The stents were coated differently, with each receiving either micro or nanoparticles separately demonstrate the potential for improved coating mass transfer efficiency, a desired prolonged drug release profile, and minimal coating time, suggesting a promising approach to enhance the treatment of in-stent restenosis (ISR) and arterial diseases. • The study demonstrates the effectiveness and reliability of the Quality by Design approach for coating micro or nanoparticles onto drug-eluting devices, resulting in improved product quality-a first in the field. • Comparative study of process parameters for coating micro and nanoparticles on drug-eluting stents-for the first time in the field. Cytotoxic drugs with non-biodegradable or biodegradable polymeric coated stents induce apoptosis and also lead to complications like local tissue inflammation. This study is aimed at demonstrating the quality by design (QbD) approach in the development of nano- and micro-particles coated drug-eluting stents (DES) encapsulating a cytostatic drug in biodegradable polymer with the potential to produce safe, targeted, and efficient drug delivery for the amelioration of life-threatening arterial diseases. Freeze-dried sirolimus (SRL) encapsulated poly lactic-co-glycolic acid (PLGA) nano- and micro-particles were fabricated by solvent evaporation technique and characterized for various physicochemical parameters like structural and thermal analyses, crystallinity, particle size, morphology, drug entrapment, and drug release rate. QbD relied on three critical process parameters (CPP), including nitrogen pressure, solution flow rate, and distance, while critical quality attributes (CQA) such as coating mass transfer efficiency, coating uniformity, drug elution rate, drug content on the stent, and coating time, were evaluated as dependent variables. The particles were coated on the cobalt-chromium-L605 alloy stent platform. The central composite design followed by multiple linear regression analysis and 3D plots were used for analyzing the impact of the dependent variables on the CPP. FTIR analysis confirmed drug-excipient compatibility. Freeze-dried particles exhibited sizes of 4.53 ± 2.3 μm for Microparticles (MPs) and 158 ± 3.1nm for Nanoparticles (NPs), with high drug entrapment of 96.8 ± 1.08% and 86.21 ± 2.08%, respectively. DSC and XRD analyses supported drug entrapment findings. Furthermore, an initial burst release of SRL 16 ± 2.08% for MPs and 25 ± 3.26% for NPs occurred in the initial 0.5 h, followed by prolonged drug release over 48 h. Design of experiment (DOE) analysis of the CQA indicated optimal coating mass transfer efficiency, improved coating uniformity, and drug elution rate. This study demonstrates the effectiveness of developing drug-loaded biodegradable micro/nano-particles and the reliability of the QbD approach in the use of these particulate systems for coating drug eluting devices - a first in the field. Besides, the study highlights a comparative investigation of process parameters for coating MPs and NPs on DES for the first time in the field. The results from the present study indicate the potential of micro/nanoparticles coated DES to ease the treatment of In-Stent Restenosis (ISR) and arterial diseases. Graphical abstract Download : Download high-res image (203KB) Download : Download full-size image

In Vitro Release Study of Sirolimus from a PDLLA Matrix on a Bioresorbable Drug-Eluting Stent

The Effect of Fluid Shear Stress on the In Vitro Release Kinetics of Sirolimus from PLGA Films

In vitro drug release profiling of Sirolimus polymeric microparticles coated long-acting stents

Preparation and Evaluation of Poly(d, L-lactic Acid)/poly(l-Lactide-co-ε-caprolactone) Blends for Tunable Sirolimus Release

In Vitro and in Vivo Changes to PLGA/sirolimus Coating on Drug Eluting Stents

Drug Release Kinetics from a Drug-Eluting Stent with Asymmetrical Coat.

Sirolimus micro/nano particles coated drug-eluting stents using QbD paradigm: Potential approach for the amelioration of arterial diseases

In Vitro Release of Rapamycin Sustained Eluting Stent Detected by a New Designed Circulating Device

Modulating Drug Release from Short Poly(ethylene Glycol) Block Initiated Poly(L-lactide) Di-block Copolymers

AS-30: the Preclinical Assessment of a Novel Biodegradable Rapid Prohealing Polymer with Sirolimus -Eluting Coating Stent in Porcine Model

The Design and Pharmacokinetics in Vivo of Rapamycin-PLGA Membrane Eluting Stent

Design, preparation and performance of a novel drug-eluting stent with multiple layer coatings.

Pharmacodynamics of China-made rapamycin-polylactide-co-glycolide peripheral arterial eluting stent membrane: in vitro experiment]

Controlled Slow-Release Drug-Eluting Stents for the Prevention of Coronary Restenosis: Recent Progress and Future Prospects

Effectiveness and safety of the sirolimus-eluting stents coated with bioabsorbable polymer coating in human coronary arteries.

Drug-Eluting Coronary Stents Coated with Polysulfone-Poly(ethylene Oxide) Block Copolymer by Ultrasonic Spray

Evaluation of Two Polymeric Blends (EVA/PLA and EVA/PEG) As Coating Film Materials for Paclitaxel-Eluting Stent Application

Pharmacodymanics of China-made Rapamycin-Polylactide Coglycotide Peripheral Arterial Eluting Stent Membrane: in Vitro Experiment

Micro Structure and in Vivo Research of Co-Cr Biodegradable Coating Sirolimus Eluting Stent

Efficacy and Safety of the Novel Sirolimus-Eluting, Biodegradable Polymer Coated Stent in Human Coronary Lesions

An Overview of In Vitro Drug Release Methods for Drug-Eluting Stents